RxDoctor Payments Data

Carol Roge, MD

Family Medicine · Sioux City, IANPI 1295794402

Payments from drug & device makers

$1,971in general payments, 2019–2025

Across 129 payments — averaging $15.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$430
  • GSK$162
  • Amgen$144
  • Pfizer$133
  • Novo Nordisk$126
  • Astellas Pharma US Inc$115
  • plus $861 from 23 others

What the payments were for

  • Food & beverage$1,971100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,971 in reported general payments places this provider in the 85th percentile of 1,357 family medicine providers in Iowa.

See all family medicine providers in Iowa

Medicare billing

Part B allowed, 2024
$176,706
Medicare patients
331
Services billed
4,907

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide55$56,279
EliquisApixaban94$52,990
Trelegy ElliptaFluticasone/Umeclidin/Vilanter71$44,820
JardianceEmpagliflozin36$36,231
FarxigaDapagliflozin Propanediol35$34,679
Breo ElliptaFluticasone/Vilanterol32$13,401
XareltoRivaroxaban13$10,915
Spiriva RespimatTiotropium Bromide18$8,794
Tresiba Flextouch U-100Insulin Degludec12$6,896
Memantine Hcl ErMemantine Hcl68$5,156
Atorvastatin Calcium574$3,907
Pantoprazole Sodium316$3,581
Levothyroxine Sodium513$3,287
Striverdi RespimatOlodaterol Hcl12$2,804
Fluticasone-SalmeterolFluticasone Propion/Salmeterol16$2,799

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$162$58,221103 claims
Novo NordiskOzempic$126$56,27955 claims
PfizerEliquis$133$52,99094 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Striverdi Respimat$41$47,82966 claims
AstraZenecaFarxiga$39$34,67935 claims
Johnson & JohnsonXarelto$27$10,91513 claims
AbbVieSynthroid$430$1,98343 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,357 family medicine providers in Iowa.

Other family medicine in Sioux City

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →